Novo Nordisk A/S ADR NVO
-
Johnson & Johnson: An Uncommon Opportunity
By Rajiv Tarigopula : Johnson & Johnson ( JNJ ) , one of the world's leaders in the pharmaceutical, medical devices, and general consumer products industries, is a supreme opportunity for long-term value investors. Trading near $63 today, Johnson & Johnson has a very healthy dividend yield of over
-
Novo Nordisk's Oral Insulin Effort May Bear Big Rewards
By Derek Lowe : Bloomberg has an article on Novo Nordisk ( NVO ) and their huge ongoing effort to come up with an orally available form of insulin. That's been a dream for a long time now …
-
9 High-Growth Healthcare Stocks With Strong Inventory Trends
By Kapitall : Do you consider a stock's sales trends when comparing names? For ideas on how to start your own sales analysis, we ran a screen. We began by screening the healthcare sector for stocks with high growth prospects, with 5-year projected EPS growth above 15%. We then screened these names
-
Amylin Goes A Little Wizard Of Oz On Shareholders
By Stephen Simpson : "Pay no attention to the man behind the curtain!" L. Frank Baum, The Wonderful Wizard Of Oz For a company that owes about 45% of its post-March 28 market cap to buyout rumors, biopharma Amylin Pharmaceuticals ( AMLN ) continues to be stubbornly silent on the question of whether
-
New Morningstar Analyst Report - MannKind Corporation
… disappointing sales and was linked to a potential risk of lung cancer in former smokers, causing diabetes experts such as Novo Nordisk NVO and Eli Lilly LLY to withdraw their own inhaled insulin products from late-stage trials. Although MannKind plans to remedy …
-
Prolor's Advantage In The Obesity Drug Race
- By Aryeh Katz : Obesity is fast becoming America's number one healthcare issue, eating up an increasingly gluttonous percentage of both the Medicare and Medicaid pie. Americans of every age, socio-economic and ethnic background suffer from the malady. Between 1987 and 2002 the number of obese ...
-
Merck: Will Singulair Expiration Sink Its Stock?
By Mel Daris : Would you want to buy stock in a pharmaceutical company whose biggest selling product, worth over $5 billion in annual revenues, is about to go generic? Merck ( MRK ) sells a large number of prescription drugs, produces and markets vaccines for people and animals and is also the ...
-
Eli Lilly's Valuation May Prove To Be A Good Investment Opportunity
By ValueMax : Eli Lilly ( LLY ) , the $25 billion in sales, pharmaceutical company, is currently at a crossroads which will dictate the future direction of its share price over the next 2 years. Like all drug development companies, future success always depends on the next new blockbuster drug. ...
-
3 'Big Pharma' Stocks To Consider Now
By Stock Croc : Pharmaceutical research, development, and marketing are not limited by national borders. The larger of these companies are global players, so I thought I would look across the ocean to see what some of the major European pharmaceutical giants are up to. Sanofi ( SNY ) is continental
-
Trading Margins For Growth Isn't Going To Help Becton Dickinson
By Stephen Simpson : Becton Dickinson ( BDX ) has been a single-digit grower for most of the past decade, and that really hasn't seemed to bother anybody. There's nothing wrong with consistent high-quality performance, particularly when accompanied by improving free cash flow conversion. Although